Afamelanotide (Melanotan-1): An Approved Orphan Drug With Modest, Single-Sponsor Evidence

Afamelanotide stands out in the “melanotan” family because it is an actual approved medicine, not a gray-market product. Sold under the brand name Scenesse, it is a drug that a doctor implants under the skin to treat a rare inherited disease that makes people extremely sensitive to light. That difference is worth keeping straight. Most of what you read about “melanotan” online is really about Melanotan-2, an unapproved injectable tanning peptide. That is a different molecule with a different safety record. This profile is about the approved drug: what it genuinely does, what backs it up, and where the evidence is weaker than the headlines make it sound.

What it is

Afamelanotide is a synthetic tridecapeptide — a chain of 13 amino acids (the building blocks of proteins). It is built as an analog (a close copy) of a hormone your body already makes, called α-melanocyte-stimulating hormone (α-MSH), which belongs to a group of signaling molecules known as the melanocortins. Its amino-acid sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. It differs from the natural hormone at just two spots: methionine-4 is swapped for norleucine, and L-phenylalanine-7 is swapped for D-phenylalanine. Those two small changes make the molecule harder for the body’s enzymes to break down and slow how quickly it lets go of its target. That is why its developers called it “ultralong” acting.

Here is how it works. Afamelanotide is an agonist (a molecule that switches a receptor on) at the melanocortin-1 receptor, or MC1R, which sits on the melanocytes — the pigment-making cells in your skin. It has weaker effects on the other melanocortin receptors. Flipping on MC1R raises a cell messenger called cAMP, which kicks off a chain of signals (involving the proteins PKA, CREB, and MITF) that cranks up the enzymes that make pigment (tyrosinase and its relatives). The end result is more eumelanin — the brown-black pigment that protects skin from light — and this happens without any sun exposure at all. You will often read that these analogs are about 1,000 times more potent than the natural hormone. That number shows up in second-hand sources; the original developers did describe them as far more potent in early lab tests, but treat the exact “1,000 times” figure as a rough, second-hand estimate rather than a confirmed measurement.

The claims

There is only one approved use. Afamelanotide is authorised to increase pain-free time in the light and to prevent phototoxic reactions (painful skin reactions triggered by light) in adults with confirmed erythropoietic protoporphyria, or EPP. EPP is a rare genetic disorder in which sunlight causes severe burning skin pain. By boosting the skin’s baseline level of eumelanin, the drug is meant to give these patients more bearable time outdoors.

Outside of EPP, afamelanotide has been studied — but not approved — for vitiligo (a condition that causes patches of lost skin color), where it was tested as an add-on to narrowband UV-B light therapy, as well as for polymorphous light eruption, solar urticaria, and other conditions where light hurts the skin. Most of these research efforts are small or have never been published.

It is also worth being clear about the cosmetic “tanning” claims that dominate online talk about “melanotan.” Those mostly belong to Melanotan-2, not to the pharmaceutical drug afamelanotide. Those tanning products are unapproved and illegal to sell as medicines.

What the evidence actually shows

For its one approved use, the backbone is two phase 3 randomized, double-blind, placebo-controlled trials (the most rigorous kind, where neither patients nor doctors know who got the real drug). They were published together in the New England Journal of Medicine in 2015. One ran in Europe (74 patients) and one in the United States (94 patients), both using a 16 mg subcutaneous (under the skin) implant given every 60 days. In both, the main thing measured was how many hours of pain-free time in direct sun patients recorded for themselves.

Both trials favored the drug. In the European trial, the typical (median) pain-free sun time was 6.0 hours, versus 0.8 hours for placebo (P=0.005, meaning the result was very unlikely to be chance). In the US trial, it was 69.4 hours versus 40.8 hours (P=0.04). Phototoxic reactions dropped significantly in the European trial (77 versus 146, P=0.04) but not in the US trial. Quality-of-life scores improved significantly in the US trial (day-180 change 51.1 versus 36.8, P=0.02), but in the European trial the difference fell just short of significance (day-270 score 79.7 versus 67.2, P=0.06).

There is also some supporting real-world data. A single-center Dutch study of 117 patients (JAMA Dermatology, 2020) reported about 6.1 more hours per week spent outside and a 14% improvement in quality of life (both P<0.001), though the number and length of reactions did not change significantly. A two-center observational study of 115 patients followed for up to eight years (British Journal of Dermatology, 2015) reported quality-of-life scores climbing from 31% to 74% of the maximum while on treatment. For vitiligo, one randomized multicenter trial (JAMA Dermatology, 2015) found that afamelanotide plus narrowband UV-B brought somewhat more repigmentation than UV-B alone (48.6% versus 33.3% at day 168), with a faster response in darker-skinned patients — but that trial was small and tested the drug as an add-on, not at the level needed for approval.

This is more and better evidence than most peptides in this area can show, which is why the EPP use earns a “Preliminary” (grade 6) grade rather than something weaker. But it does not reach an unqualified “Strong” (grade 8–10) rating, for a few honest reasons. The two main trials used different time windows and produced very different effect sizes. The main thing measured was sun time that patients logged themselves and that depends on their behavior, which can be biased even in a blinded study. The drop in phototoxic reactions was not consistent between the two trials, and the European quality-of-life result was not significant. Most importantly, nearly every dataset showing the drug works is sponsored by or financially tied to the manufacturer, Clinuvel. The evidence is real and has been vetted by regulators, but it comes from a single sponsor, the effect is modest, and the results are shaky at the level of individual measurements. For tanning and every non-EPP use, there are no adequate outcome trials, and the grade drops to theoretical or no credible evidence.

Safety and side effects

In the controlled trials, the side effects of pharmaceutical afamelanotide were generally mild to moderate, and there were no deaths linked to the treatment. The approved label lists these among the more common side effects: reactions at the implant site (including discoloration at the site in roughly 10% of patients), nausea, throat pain, cough, fatigue, dizziness, skin darkening, drowsiness, new moles (melanocytic nevi), respiratory tract infection, and skin irritation. Long-term studies have reported that patients tolerate it well.

Because the drug revs up the pigment cells (melanocytes), regular skin and mole checks are advised. The data on the approved drug have not shown a higher rate of melanoma (a serious skin cancer), but there are no long-term studies large enough to settle the question, so this theoretical concern is not fully put to rest.

A separate and more worrying safety picture belongs to the gray-market drug Melanotan-2, which should not be mixed up with afamelanotide. The published harms from Melanotan-2 are mostly case reports (single-patient accounts), including moles darkening and growing, abnormal moles (dysplastic nevi), and melanoma appearing around the time of use — for example, a documented case in a teenager who had a family syndrome of moles and melanoma and combined Melanotan-2 with tanning beds. There are also risks from non-sterile or fake product. How often any of these actually happen is unknown.

Legal and regulatory status

Afamelanotide is a prescription orphan drug (a drug approved for a rare disease). The European Commission granted marketing authorisation on 22 December 2014, “under exceptional circumstances,” making it the first approved treatment for EPP. The FDA approved it on 8 October 2019 (NDA 210797, sponsor Clinuvel) as a 16 mg subcutaneous (under the skin) implant, placed only by a trained healthcare professional and available only through restricted distribution. It is not something you inject yourself.

Melanotan-2, by contrast, is not approved as a medicine anywhere. Australia’s Therapeutic Goods Administration states that it is not approved, that its development was stopped over safety concerns, and that advertising or supplying it is illegal — citing melanoma risk and body-wide effects such as nausea, flushing, and prolonged erections. UK regulators likewise treat “melanotan” tanning products as unlicensed medicines.

In sport, melanocortin and α-MSH analogs are widely considered banned substances, but anyone who needs a definite answer should check the current WADA Prohibited List directly rather than trust second-hand claims about a particular category.

Bottom line

Afamelanotide is the rare melanotan-family compound that is a real, approved medicine — but only for one rare disease, erythropoietic protoporphyria, and only as an implant placed by a clinician. For that narrow use, it is backed by two randomized placebo-controlled trials plus observational studies, which is a stronger track record than most peptides can claim. The honest caveats: the effect is modest, the things measured are shaky and reported by patients themselves, the two trials disagreed, and almost all the data come from a single sponsor. It is not a tanning shortcut, and it is absolutely not the same thing as the unapproved, illegal Melanotan-2 sold online. If you have seen “melanotan” marketed for cosmetic tanning, that is a different and unproven product that carries real, documented harms.

Sources

• Langendonk et al. Afamelanotide for Erythropoietic Protoporphyria. NEJM 2015 (full text)
• Langendonk et al. NEJM 2015 (PubMed)
• FDA approval letter, NDA 210797
• Scenesse prescribing information (DailyMed)
• EMA EPAR: Scenesse (EU authorisation 22 Dec 2014)
• WADA Prohibited List
• Wensink et al. JAMA Dermatology 2020 (post-authorization cohort)
• Biolcati et al. British Journal of Dermatology 2015 (long-term cohort)
• Lim et al. Afamelanotide and Narrowband UV-B for Vitiligo. JAMA Dermatology 2015
• Hadley & Hruby. Discovery and development of Melanotan-I and -II. 1998
• Melanotan-2 melanoma case report. Dermatology Practical & Conceptual 2012
• Afamelanotide (background overview)
• Drugs.com: Scenesse FDA approval history
• UNSW / TGA: Melanotan-II warning